Total Payments
$59,925
2023 Payments
$148.98
Companies
21
Transactions
47
Medicare Patients
1,327
Medicare Billing
$248,701
Payment Breakdown by Category
Research$59,029 (98.5%)
Food & Beverage$896.60 (1.5%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $59,029 | 7 | 98.5% |
| Food and Beverage | $896.60 | 40 | 1.5% |
Payments by Type
Research
$59,029
7 transactions
General
$896.60
40 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Eli Lilly and Company | $59,029 | 7 | $0 (2023) |
| SANOFI-AVENTIS U.S. LLC | $166.06 | 4 | $0 (2019) |
| Amgen Inc. | $163.75 | 6 | $0 (2020) |
| AstraZeneca Pharmaceuticals LP | $97.88 | 3 | $0 (2018) |
| SANOFI PASTEUR INC. | $95.61 | 1 | $0 (2019) |
| Janssen Pharmaceuticals, Inc | $51.85 | 3 | $0 (2018) |
| PFIZER INC. | $36.06 | 4 | $0 (2018) |
| Astellas Pharma US Inc | $36.00 | 2 | $0 (2018) |
| GE HEALTHCARE | $35.89 | 2 | $0 (2020) |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $30.32 | 2 | $0 (2018) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2023 | $148.98 | 1 | Eli Lilly and Company ($148.98) |
| 2022 | $6,348 | 3 | Eli Lilly and Company ($6,348) |
| 2021 | $52,532 | 3 | Eli Lilly and Company ($52,532) |
| 2020 | $57.18 | 3 | Amgen Inc. ($20.51) |
| 2019 | $209.69 | 4 | SANOFI PASTEUR INC. ($95.61) |
| 2018 | $435.36 | 19 | Amgen Inc. ($128.34) |
| 2017 | $194.37 | 14 | SANOFI-AVENTIS U.S. LLC ($34.39) |
All Payment Transactions
47 individual payment records from CMS Open Payments — Page 1 of 2
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 04/28/2023 | Eli Lilly and Company | — | — | In-kind items and services | $148.98 | Research |
| Study: EFFICACY AND SAFETY OF TIRZEPATIDE ONCE WEEKLY VERSUS PLACEBO FOR MAINTENANCE OF WEIGHT LOSS IN PARTICIPANTS WITHOUT TYPE 2 DIABETES WHO HAVE OBESITY OR ARE OVERWEIGHT WITH WEIGHT-RELATED COMORBIDITIES: A RANDOMIZED DOUBLE-BLIND PLACEBO-CONTROLLED TRIAL (SURMOUNT-4) | ||||||
| 10/04/2022 | Eli Lilly and Company | — | — | Cash or cash equivalent | $4,364.00 | Research |
| Study: EFFICACY AND SAFETY OF TIRZEPATIDE ONCE WEEKLY VERSUS PLACEBO FOR MAINTENANCE OF WEIGHT LOSS IN PARTICIPANTS WITHOUT TYPE 2 DIABETES WHO HAVE OBESITY OR ARE OVERWEIGHT WITH WEIGHT-RELATED COMORBIDITIES: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL (SURMOUNT-4) | ||||||
| 01/31/2022 | Eli Lilly and Company | — | — | In-kind items and services | $1,052.00 | Research |
| Study: A PHASE 2 STUDY OF ONCE-DAILY LY3502970 COMPARED WITH PLACEBO AND ONCE-WEEKLY DULAGLUTIDE IN PARTICIPANTS WITH TYPE 2 DIABETES MELLITUS | ||||||
| 01/19/2022 | Eli Lilly and Company | — | — | In-kind items and services | $932.00 | Research |
| Study: EFFICACY AND SAFETY OF TIRZEPATIDE ONCE WEEKLY VERSUS PLACEBO FOR MAINTENANCE OF WEIGHT LOSS IN PARTICIPANTS WITHOUT TYPE 2 DIABETES WHO HAVE OBESITY OR ARE OVERWEIGHT WITH WEIGHT-RELATED COMORBIDITIES: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL (SURMOUNT-4) | ||||||
| 09/09/2021 | Eli Lilly and Company | — | — | In-kind items and services | $4,927.83 | Research |
| Study: A PHASE 2 STUDY OF ONCE-DAILY LY3502970 COMPARED WITH PLACEBO AND ONCE-WEEKLY DULAGLUTIDE IN PARTICIPANTS WITH TYPE 2 DIABETES MELLITUS | ||||||
| 06/29/2021 | Eli Lilly and Company | — | — | Cash or cash equivalent | $42,455.00 | Research |
| Study: EFFICACY AND SAFETY OF TIRZEPATIDE ONCE WEEKLY VERSUS PLACEBO FOR MAINTENANCE OF WEIGHT LOSS IN PARTICIPANTS WITHOUT TYPE 2 DIABETES WHO HAVE OBESITY OR ARE OVERWEIGHT WITH WEIGHT-RELATED COMORBIDITIES: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL (SURMOUNT-4) | ||||||
| 03/03/2021 | Eli Lilly and Company | — | — | In-kind items and services | $5,149.01 | Research |
| Study: EFFICACY AND SAFETY OF TIRZEPATIDE ONCE WEEKLY VERSUS PLACEBO FOR MAINTENANCE OF WEIGHT LOSS IN PARTICIPANTS WITHOUT TYPE 2 DIABETES WHO HAVE OBESITY OR ARE OVERWEIGHT WITH WEIGHT-RELATED COMORBIDITIES: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL (SURMOUNT-4) | ||||||
| 02/12/2020 | Amgen Inc. | EVENITY (Biological), Prolia | Food and Beverage | In-kind items and services | $20.51 | General |
| Category: Bone Health | ||||||
| 01/22/2020 | Biogen, Inc. | SPINRAZA (Biological) | Food and Beverage | In-kind items and services | $18.74 | General |
| Category: NEUROLOGY | ||||||
| 01/01/2020 | GE HEALTHCARE | — | Food and Beverage | Cash or cash equivalent | $17.93 | General |
| 09/17/2019 | SANOFI-AVENTIS U.S. LLC | DIABETES - DISEASE (Drug) | Food and Beverage | In-kind items and services | $77.17 | General |
| 08/21/2019 | SANOFI PASTEUR INC. | FLUBLOK QUADRIVALENT (Drug), FLUZONE HIGH-DOSE | Food and Beverage | In-kind items and services | $95.61 | General |
| Category: VACCINES | ||||||
| 05/08/2019 | GE HEALTHCARE | — | Food and Beverage | Cash or cash equivalent | $17.96 | General |
| 02/21/2019 | Medtronic MiniMed, Inc. | Minimed 670G System (Device) | Food and Beverage | In-kind items and services | $18.95 | General |
| Category: Durable Pump | ||||||
| 11/07/2018 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | XIFAXAN (Drug) | Food and Beverage | In-kind items and services | $10.63 | General |
| Category: GASTROENTEROLOGY | ||||||
| 10/24/2018 | Amgen Inc. | Prolia (Biological), Repatha | Food and Beverage | In-kind items and services | $14.59 | General |
| Category: Endocrinology | ||||||
| 10/17/2018 | Janssen Pharmaceuticals, Inc | XARELTO (Drug), INVOKANA | Food and Beverage | In-kind items and services | $18.07 | General |
| Category: Cardiovascular & Metabolism | ||||||
| 08/22/2018 | PFIZER INC. | CHANTIX (Drug), ELIQUIS | Food and Beverage | In-kind items and services | $11.92 | General |
| Category: NEUROSCIENCE;TOBACCO DEPENDENCE | ||||||
| 08/01/2018 | Amgen Inc. | Repatha (Biological) | Food and Beverage | In-kind items and services | $13.80 | General |
| Category: Cardiology | ||||||
| 07/19/2018 | Novo Nordisk Inc | Victoza (Drug), Tresiba, Xultophy 100/3.6 | Food and Beverage | In-kind items and services | $12.39 | General |
| Category: Diabetes | ||||||
| 07/17/2018 | Amgen Inc. | Repatha (Biological) | Food and Beverage | In-kind items and services | $85.16 | General |
| Category: Cardiology | ||||||
| 06/27/2018 | Lilly USA, LLC | TRULICITY (Drug), BASAGLAR | Food and Beverage | In-kind items and services | $12.33 | General |
| Category: Diabetes | ||||||
| 05/23/2018 | Merck Sharp & Dohme Corporation | JANUVIA (Drug), STEGLATRO | Food and Beverage | In-kind items and services | $13.87 | General |
| Category: ENDOCRINOLOGY | ||||||
| 05/02/2018 | Boehringer Ingelheim Pharmaceuticals, Inc. | TRADJENTA (Drug), JARDIANCE, GLYXAMBI | Food and Beverage | In-kind items and services | $16.97 | General |
| Category: DIABETES | ||||||
| 04/25/2018 | PFIZER INC. | CHANTIX (Drug), ELIQUIS | Food and Beverage | In-kind items and services | $11.48 | General |
| Category: NEUROSCIENCE;TOBACCO DEPENDENCE | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| EFFICACY AND SAFETY OF TIRZEPATIDE ONCE WEEKLY VERSUS PLACEBO FOR MAINTENANCE OF WEIGHT LOSS IN PARTICIPANTS WITHOUT TYPE 2 DIABETES WHO HAVE OBESITY OR ARE OVERWEIGHT WITH WEIGHT-RELATED COMORBIDITIES: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL (SURMOUNT-4) | Eli Lilly and Company | $52,900 | 4 |
| A PHASE 2 STUDY OF ONCE-DAILY LY3502970 COMPARED WITH PLACEBO AND ONCE-WEEKLY DULAGLUTIDE IN PARTICIPANTS WITH TYPE 2 DIABETES MELLITUS | Eli Lilly and Company | $5,980 | 2 |
| EFFICACY AND SAFETY OF TIRZEPATIDE ONCE WEEKLY VERSUS PLACEBO FOR MAINTENANCE OF WEIGHT LOSS IN PARTICIPANTS WITHOUT TYPE 2 DIABETES WHO HAVE OBESITY OR ARE OVERWEIGHT WITH WEIGHT-RELATED COMORBIDITIES: A RANDOMIZED DOUBLE-BLIND PLACEBO-CONTROLLED TRIAL (SURMOUNT-4) | Eli Lilly and Company | $148.98 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2021 | 16 | 599 | 784 | $310,455 | $132,385 |
| 2020 | 18 | 728 | 926 | $285,567 | $116,316 |
Total Patients
1,327
Total Services
1,710
Medicare Billing
$248,701
Procedure Codes
34
All Medicare Procedures & Services
34 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| A9584 | Iodine 1-123 ioflupane, diagnostic, per study dose, up to 5 millicuries | Office | 2021 | 24 | 24 | $69,264 | $48,058 | 69.4% |
| G0439 | Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | Office | 2021 | 158 | 158 | $42,734 | $21,420 | 50.1% |
| 78452 | Nuclear medicine study of vessels of heart using drugs or exercise multiple studies | Office | 2021 | 41 | 41 | $41,311 | $16,214 | 39.2% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 124 | 203 | $53,990 | $12,573 | 23.3% |
| 78803 | Spect nuclear medicine localization of tumor or inflammation or study of distribution of radioactive tracer in single area, 1 day of imaging | Office | 2021 | 30 | 30 | $24,738 | $9,587 | 38.8% |
| J2785 | Injection, regadenoson, 0.1 mg | Office | 2021 | 35 | 140 | $17,360 | $6,660 | 38.4% |
| 78306 | Bone and/or joint imaging, whole body | Office | 2021 | 17 | 17 | $10,863 | $4,253 | 39.2% |
| 78227 | Imaging of liver and bile duct system with use of drugs | Office | 2021 | 11 | 11 | $10,362 | $3,942 | 38.0% |
| G0438 | Annual wellness visit; includes a personalized prevention plan of service (pps), initial visit | Office | 2021 | 15 | 15 | $5,145 | $2,573 | 50.0% |
| G0402 | Initial preventive physical examination; face-to-face visit, services limited to new beneficiary during the first 12 months of medicare enrollment | Office | 2021 | 12 | 12 | $4,128 | $2,063 | 50.0% |
| 90682 | Vaccine for influenza derived from dna for injection into muscle, quadrivalent, preservative and antibiotic free | Office | 2021 | 21 | 21 | $2,688 | $1,366 | 50.8% |
| A9500 | Technetium tc-99m sestamibi, diagnostic, per study dose | Office | 2021 | 44 | 44 | $19,688 | $1,173 | 6.0% |
| 99204 | New patient outpatient visit, total time 45-59 minutes | Office | 2021 | 11 | 11 | $3,773 | $886.21 | 23.5% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 15 | 16 | $2,992 | $754.65 | 25.2% |
| G0008 | Administration of influenza virus vaccine | Office | 2021 | 25 | 25 | $875.00 | $437.86 | 50.0% |
| A9503 | Technetium tc-99m medronate, diagnostic, per study dose, up to 30 millicuries | Office | 2021 | 16 | 16 | $544.00 | $424.80 | 78.1% |
| A9584 | Iodine 1-123 ioflupane, diagnostic, per study dose, up to 5 millicuries | Office | 2020 | 19 | 19 | $54,834 | $35,525 | 64.8% |
| G0439 | Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | Office | 2020 | 141 | 141 | $33,671 | $16,716 | 49.6% |
| 78452 | Nuclear medicine study of vessels of heart using drugs or exercise multiple studies | Office | 2020 | 36 | 36 | $35,880 | $14,046 | 39.1% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Office | 2020 | 139 | 227 | $50,780 | $11,011 | 21.7% |
| 78306 | Bone and/or joint imaging, whole body | Office | 2020 | 30 | 32 | $20,480 | $7,840 | 38.3% |
| 78803 | Spect nuclear medicine localization of tumor or inflammation or study of distribution of radioactive tracer in single area, 1 day of imaging | Office | 2020 | 20 | 20 | $16,374 | $6,192 | 37.8% |
| J2785 | Injection, regadenoson, 0.1 mg | Office | 2020 | 33 | 132 | $16,076 | $6,068 | 37.7% |
| G0438 | Annual wellness visit; includes a personalized prevention plan of service (pps), initial visit | Office | 2020 | 23 | 23 | $8,071 | $3,999 | 49.5% |
| 90682 | Vaccine for influenza for injection into muscle | Office | 2020 | 57 | 57 | $5,422 | $3,452 | 63.7% |
About Dr. Royce Solano, MD
Dr. Royce Solano, MD is a Internal Medicine healthcare provider based in Colorado Springs, Colorado. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 03/01/2006. The National Provider Identifier (NPI) number assigned to this provider is 1184691982.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Royce Solano, MD has received a total of $59,925 in payments from pharmaceutical and medical device companies, with $148.98 received in 2023. These payments were reported across 47 transactions from 21 companies. The most common payment nature is "" ($59,029).
As a Medicare-enrolled provider, Solano has provided services to 1,327 Medicare beneficiaries, totaling 1,710 services with total Medicare billing of $248,701. Data is available for 2 years (2020–2021), covering 34 distinct procedure/service records.
Ad
Practice Information
- Specialty Internal Medicine
- Other Specialties Internal Medicine
- Location Colorado Springs, CO
- Active Since 03/01/2006
- Last Updated 08/30/2018
- Taxonomy Code 207R00000X
- Entity Type Individual
- NPI Number 1184691982
Products in Payments
- Repatha (Biological) $113.86
- FLUBLOK QUADRIVALENT (Drug) $95.61
- DIABETES - DISEASE (Drug) $77.17
- HYPERLIPIDEMIA - DISEASE (Drug) $54.50
- INVOKANA (Drug) $33.78
- Prolia (Biological) $29.38
- CHANTIX (Drug) $23.40
- EVENITY (Biological) $20.51
- TOUJEO (Drug) $19.77
- Minimed 670G System (Device) $18.95
- SPINRAZA (Biological) $18.74
- Myrbetriq (Drug) $18.51
- XARELTO (Drug) $18.07
- VESICARE (Drug) $17.49
- TRADJENTA (Drug) $16.97
- Quadramet (Drug) $16.59
- XIFAXANIBSD (Drug) $16.06
- PRALUENT (Drug) $14.62
- JANUVIA (Drug) $13.87
- JARDIANCE (Drug) $13.35
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Internal Medicine Doctors in Colorado Springs
Dr. Luke Webb, Md, MD
Internal Medicine — Payments: $314,231
Internal Medicine $314,231
Dr. Bradley Mikaelian, M.d, M.D
Internal Medicine — Payments: $289,154
Internal Medicine $289,154
Preetham Reddy, M.d.,C.m, M.D.,C.M
Internal Medicine — Payments: $55,090
Internal Medicine $55,090
Mr. Gary Simpson, D.o, D.O
Internal Medicine — Payments: $50,674
Internal Medicine $50,674
Mr. Sridhar Reddy, Md, MD
Internal Medicine — Payments: $21,467
Internal Medicine $21,467
Dr. Jaime Gonzalez, M.d, M.D
Internal Medicine — Payments: $14,130
Internal Medicine $14,130